An observational study in Small-cell Lung Cancer, sponsored by Duke University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Duke University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The overall objective of this project is to prospectively collect blood samples from patients with small cell lung cancer (SCLC) who are initiating or receiving systemic therapy. These samples will then be analyzed through a variety of assays to better characterize SCLC treatment in the real-world setting. Studies may include, but are not limited to, the following: 1) predictors of response to treatment, 2) identification of predictive biomarkers for treatment-related toxicities, including but not limited to cytokine release syndrome (CRS) and/or immune effector cell-associated neurotoxicity syndrome (ICANS) in patients receiving tarlatamab or other T cell-engaging therapies, 3) characterization of the immune cell environment induced by systemic therapies, 4) identification of resistance mechanisms to treatment, and 5) development of potential translational correlates.
For participants receiving tarlatamab: The investigators will prospectively collect blood samples from patients on days 1, 8, and 15 of tarlatamab treatment, as well as after each interval scan for disease monitoring. The investigators will also collect patient data including demographics and baseline characteristics, primary diagnosis, treatment history, and disease monitoring and progression.
For participants receiving other systemic therapies (Chemotherapy, Immune Checkpoint Inhibitors, Antibody-Drug Conjugates, and Future/Novel Treatments): The investigators will prospectively collect blood samples from patients on Cycle 1 Day 1, Cycle 2 Day 1 of treatment, as well as after each interval scan for disease monitoring. The investigators will also collect patient data including demographics and baseline characteristics, primary diagnosis, treatment history, and disease monitoring and progression.
1,303 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.
This study's planned enrollment of 100 is below the median of 137 across 144 observational studies indexed under Small Cell Lung Carcinoma.
Browse Small Cell Lung Carcinoma studies →Duke University is the lead sponsor of 2,064 studies on the registry; 271 are open to participants now.
Of its 204 completed or terminated interventional studies of FDA-regulated products, 170 (83%) have results posted.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Nov 18, 2026. See what changed
Adult patients with small cell lung cancer (SCLC) who are eligible for treatment with tarlatamab or other systemic therapies
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receiving tarlatamab as part of their routine cancer care.
Participants receiving other systemic therapies as part of their routine cancer care. This category includes, but is not limited to: platinum-etoposide chemotherapy (with or without concurrent radiation), chemoimmunotherapy (e.g., carboplatin/etoposide/atezolizumab, platinum/etoposide/durvalumab), maintenance immunotherapy (e.g., atezolizumab, durvalumab), consolidation immunotherapy (e.g., durvalumab post-chemoradiation for limited stage), lurbinectedin, antibody-drug conjugates (e.g., ifinatamab deruxtecan, sacituzumab govitecan, or other ADCs), topotecan, and any other systemic agents used in the treatment of small cell lung cancer (SCLC).
Number of blood samples collected
Number of blood samples collected to better characterize therapies in real-world setting
Time frame: Through study completion, an average of 8 times (Day 1, Day 8, Day 15, Week 6, Week 12, Week 18, Week 24, Week 36)
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Dec 2028, 23 months later.
Of 62 observational studies under Small Cell Lung Carcinoma, half reached primary completion within 77 months of starting (the median), counting those still running; a quarter within 47. This study's planned 23 months is below that.
Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Jan 2027, on Nov 18, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.